Stockhub

Aridis Pharmaceuticals, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

26 July 2022

  • curprev 18:5118:51, 26 July 2022‎ Chris talk contribs‎ 1,573 bytes +1,573‎ Created page with "Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 m..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Aridis_Pharmaceuticals,_Inc.’